NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Management of Immunotherapy- Related Toxicities, Version 1.2019
NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Management of Immunotherapy- Related Toxicities, Version 1.2019
复制标题
DOI：
--
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
John A Thompson;B. Schneider;J. Brahmer;S. Andrews;Philippe Armand;S. Bhatia;L. Budde;Luciano Costa-Lucian
中科院分区：
文献类型：
--
作者：
John A Thompson;B. Schneider;J. Brahmer;S. Andrews;Philippe Armand;S. Bhatia;L. Budde;Luciano Costa-Lucian
NCCN免疫治疗相关毒性管理指南的目的是为癌症免疫治疗引起的免疫相关不良事件的管理提供指导。NCCN免疫治疗相关毒性管理专家组是一个跨学科小组，由NCCN成员机构和ASCO的代表组成，包括在各种疾病部位具有专业知识的医学和血液肿瘤学家，以及来自皮肤科，胃肠病学，神经肿瘤学，肾脏病学，急诊医学，心脏病学，肿瘤护理和患者宣传领域的专家。几位小组代表是癌症免疫治疗学会的成员。NCCN指导方针的最初版本是根据ASCO和SITC公布的建议设计的。本期的内容是管理与免疫检查点阻断相关的毒性的建议摘录和对现有证据的回顾。有关NCCN指南的完整版本，包括管理嵌合抗原受体T细胞治疗相关毒性的建议，请访问NCCN.org. J Natl Compr CancNetw 2019;17（3）：255-289 doi：10.6004/jnccn.2019.0013 NCCN证据和共识类别1：基于高水平证据，NCCN一致认为干预是适当的。2A类：基于较低级别的证据，NCCN一致认为干预是适当的。2B类：基于较低级别的证据，NCCN一致认为干预是适当的。第3类：基于任何级别的证据，NCCN对干预是否适当存在重大分歧。除非另有说明，所有建议均为2A类。临床试验：NCCN认为，对任何癌症患者的最佳管理是在临床试验中。特别鼓励参加临床试验。
The aim of the NCCN Guidelines for Management of ImmunotherapyRelated Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neurooncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org. J Natl Compr Canc Netw 2019;17(3):255–289 doi: 10.6004/jnccn.2019.0013 NCCN CATEGORIES OF EVIDENCE AND CONSENSUS Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate. All recommendations are category 2A unless otherwise noted. Clinical trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.